Home

GREGORY L WEAVER

CIK 1251779 · Chief Financial Officer · last filed 2026-08-03

GREGORY L WEAVER is a Chief Financial Officer who has filed 64 SEC Form 4 insider transactions across 9 companies since 2007. The most recent filing shows the insider was granted $4.2K of ALT on Aug 3, 2026. Across all open-market trades the lifetime net is −$279.8K, making them a net seller over the disclosed history. Current disclosed insider exposure totals $171.1K across reported positions. 4 SEC filings were submitted jointly with ATAI Life Sciences N.V.

"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.

Loading insider history…
Disclosed Exposure

$171.1K

Companies

9

Total Filings

64

Lifetime Open-Market Net

-$279.8K

Filer Profile

Reported Address
ALTIMMUNE, INC.
910 CLOPPER ROAD, SUITE 201S
GAITHERSBURG, MD 20878
Related Filers
ATAI Life Sciences N.V. — 4 joint filings, latest 2022-03-04
Profile details as reported on the filer's SEC submissions — for individual insiders the address is often in care of the issuer. Related filers are identified from jointly filed SEC submissions and shared reported addresses. View filings on SEC EDGAR.

Holdings By Company

Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
Symbol Role Shares Price Disclosed Exposure Lifetime OM Net Filings Latest Filed
ALT Chief Financial Officer 39,831 $3.42 $136.2K $101.2K 8 2026-08-03
ATOS Former EVP, CFO, & Director 4 $2.52 $10 -$558.0K 15 2023-11-17
ATAI Chief Financial Officer 4,666 $7.39 $34.5K $70.0K 3 2022-03-04
ELOX CHIEF FINANCIAL OFFICER 26 $15.00 $390 $0 4 2020-03-16
Zyla Life Sciences (EGLT) Delisted Director — — — $0 6 2018-05-15
Fibrocell Science, Inc. (FCSC) Delisted Chief Financial Officer 667 — — $35.1K 3 2014-01-21
Imunon, Inc. (CLSN) Delisted CFO 0 $1.96 $0 $10.7K 11 2013-03-21
PONIARD PHARMACEUTICALS, INC. (PARDD) Delisted Chief Financial Officer 9,100 — — $26.3K 4 2010-02-08
Imunon, Inc. (CLN) Delisted Director 10,000 — — $35.0K 3 2008-04-29

Recent Filings

64 filings
Insider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
Filed Symbol Action Net Shares Net $ Link
2026-08-03 ALT Grant (A) +1,753 $4.2K EDGAR
2026-04-01 ALT Buy (P) +10,000 $31.5K EDGAR
2026-03-09 ALT Buy (P) +5,000 $17.7K EDGAR
2026-02-27 ALT Grant (A) — $0 EDGAR
2025-11-12 ALT Mixed +13,078 -$24.3K EDGAR
2025-10-03 ALT Grant (A) — $0 EDGAR
2025-03-14 ALT Buy (P) +10,000 $52.0K EDGAR
2024-11-12 ALT Grant (A) — $0 EDGAR
2023-11-17 ATOS Sell (S) −50,000 -$32.5K EDGAR
2023-06-20 ATOS Buy (P) +50,000 $48.5K EDGAR
Showing 1–10 of 64
Page 1 of 7
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.